Drugs / Vi-DT Typhoid Conjugate Vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04741828 | May 2021 → Oct 2024 | — | PT Bio Farma | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04051268 | Mar 2020 → Nov 2021 | — | PT Bio Farma | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vi-DT Typhoid Conjugate Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04741828 ↗ |
| Known as | Vi-DT | “Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)” NCT04051268 ↗ |
| Modality | Vaccine | “Vi-DT Typhoid Conjugate Vaccine” NCT04051268 ↗ |
| Route | Intramuscular | “intramuscularly” NCT04741828 ↗ |